An innovation to improve outcomes from DVT
K1 is an active pipeline endovascular interventional development program by Koya focused on improving overall patient access and clinical outcomes for those suffering from chronic complications from DVT.
A FDA-cleared wearable compression treatment indicated for the treatment of lymphedema, phlebolymphedema, venous insufficiency, lipedema, related conditions to chronic edema and supports mobility during treatment1.
Multiple randomized controlled studies including NILE (2022) and TEAYS (2024) showed that Dayspring provides superior outcomes in edema reduction, quality of life, and adherence compared to standard of care2,3.
Deep Vein Thrombosis (DVT) is the formation of a blood clot (thrombus) in a deep vein, most commonly in the lower extremities (leg, thigh, pelvis) but can also occur in the upper extremities. If untreated, it poses a serious risk of pulmonary embolism (PE). While often thought of as an acute condition, poorly treated DVTs can lead to chronic complications, such as Post Thrombotic Syndrome (PTS).
Learn more about our commitment to bring solutions that address unmet and undermet needs across the venous and lymphatic continuum.
.avif){kind=logo}
